CYMABAY THERAPEUTICS INC (CBAY)

US23257D1037 - Common Stock

32.17  -0.02 (-0.06%)

After market: 32.17 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CYMABAY THERAPEUTICS INC

NASDAQ:CBAY (2/22/2024, 7:00:02 PM)

After market: 32.17 0 (0%)

32.17

-0.02 (-0.06%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap3.65B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CBAY Daily chart

Company Profile

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. The company is headquartered in Newark California, California and currently employs 60 full-time employees. The company went IPO on 2014-01-16. The firm is focused on developing therapies for patients with liver and other chronic diseases. The firm's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation, and fibrosis. The company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. Its other product candidate, MBX-2982, targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.

Company Info

CYMABAY THERAPEUTICS INC

Suite 130, 7999 Gateway Blvd

Newark California CALIFORNIA 94560

P: 15102938800

CEO: Sujal Shah

Employees: 60

Website: https://www.cymabay.com/

CBAY News

News Imagea day ago - CymaBay TherapeuticsThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis

/PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other...

News Image2 days ago - CymaBay Therapeutics, Inc.CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on...

News Image6 days ago - Kahn Swick & Foti, LLCCYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY
News Image6 days ago - Seeking AlphaInventiva stock drops after delay in Phase 3 NASH trial

Inventiva (IVA) stock plummeted as it announced a delay in its Phase 3 trial for NASH candidate lanifibranor due to an adverse event. Read more here.

News Image10 days ago - Market News VideoNotable Monday Option Activity: CBAY, TTD, OSW
News Image10 days ago - Seeking AlphaLiver disease drug developers rise after Gilead-CymaBay deal (NASDAQ:GILD)

Gilead's (GILD) acquisition of CymaBay Therapeutics CBAY) boosts liver disease-focused drug developers, leading to notable gains in their stock prices. Read more here.

CBAY Twits

Here you can normally see the latest stock twits on CBAY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example